Global Link for Online Biomedical Expertise (GLOBE)

The launch of the Mass Campaign Against Meningitis A in west Africa with the new vaccine MenAfriVac

Author: World Health Organization (WHO)
Publisher: World Health Organization (WHO)
Type: News
Language: English , French
Published: 6/12/2010
Published online: 22/12/2010
Theme: Prevention and Vaccines

Designed specifically to protect against group A meningococcus, which accounts for 80-85% of cases of meningitis in the 25 countries of the African meningitis belt, the vaccine is priced at less than 0.50 US dollars per dose, and cost less than one-tenth of the 500 million US dollars usually required to develop and bring a vaccine to market.

Developed by the Meningitis Vaccine Project, a partnership between WHO and the international non-profit organization PATH, the new vaccine, MenAfriVac, provides African health authorities, for the first time, with an affordable, long-term solution that protects even young children against meningitis A.

National immunization campaigns were launched this month: on 6 December 2010 in Burkina Faso, 16 December in Mali and the campagin is scheduled to start in December in Niger.

No comments on the subject.

Top of Page